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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplastic diseases,
associated with a remarkably poor prognosis. However, the molecular mechanisms underlying the development of
PDAC remain elusive. The aim of this study was to identify genes whose expressions are correlated with a poor
prognosis in PDAC patients, and to unravel the mechanisms underlying the involvement of these genes in the
development of the cancer.
Methods: Global gene expression profiling was conducted in 39 specimens obtained from Japanese patients with
PDAC to identify genes whose expressions were correlated with a shorter overall survival. The effect of gene silencing
or overexpression of ARHGEF15 in pancreatic cancer cell lines was examined by introducing siRNAs of ARHGEF15 or
the ARHGEF15 expression vector. After assessing the effect of ARHGEF15 deregulation on the Rho-family proteins by
pull-down assay, wound healing, transwell and cell viability assays were carried out to investigate the cellular
phenotypes caused by the perturbation.
Results: The global mRNA expression profiling revealed that overexpression of ARHGEF15, a Rho-specific GEF, was
significantly associated with a poor prognosis in patients with PDAC. We also found that the depletion of ARHGEF15
by RNA interference in pancreatic cancer cell lines downregulated the activities of molecules of the Rho signaling
pathway, including RhoA, Cdc42 and Rac1. Then, we also showed that ARHGEF15 silencing significantly reduced the
motility and viability of the cells, while its overexpression resulted in the development of the opposite phenotype in
multiple pancreatic cancer cell lines.
Conclusion: These data suggest that upregulation of ARHGEF15 contributes to the development of aggressive PDAC
by increasing the growth and motility of the pancreatic cancer cells, thereby worsening the prognosis of these
patients. Therefore, ARHGEF15 could serve as a novel therapeutic target in patients with PDAC.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most aggressive cancers, and is the fourth most frequent
cause of cancer-related death in both Japan and the US.
The prognosis of patients with this disease is extremely
poor, with an overall median survival of 5 to 8 months.
Since it is difficult to diagnose pancreatic cancer at an
early stage, approximately 80 % of patients with PDAC
have unresectable disease, including locally advanced or
distant metastatic disease, at diagnosis [1, 2]. Therefore,
clarification of the molecular mechanism underlying the
exceptionally poor prognosis of PDAC, and identifica-
tion of novel therapeutic targets for the treatment of
PDAC are urgently needed.
The Rho-family GTPases are important intracellular
signaling molecules that regulate cytoskeleton
organization, gene expressions, cell cycle progression,
cell motility and other cellular processes through modu-
lating the activities of the downstream molecules, in-
cluding p21-activated kinase (PAK), Rho-kinase and the
myosin-binding subunit of myosin phosphatase [3]. Ab-
normal Rho GTPase activities have been implicated in
multiple human pathologies [4, 5]. RhoA, in particular,
is activated in several human cancers and is reported to
be involved in cancer progression and metastasis [6–9].
The Rho-family small GTPases cycle between the GTP-
bound form, which is the active form, and the GDP-
bound form, which is the inactive form, in response to
several upstream signals, including growth factors, cyto-
kines, adhesion molecules, etc. These signals activate
guanine nucleotide exchange factors (GEFs), which in
turn activate small GTPases by promoting the loading of
GTP on to the small GTPases, a rate-limiting step in
GTPase regulation [10, 11]. Accumulated reports have
shown that the GEFs for the Rho-family proteins are
deregulated in multiple types of cancers. VAV guanine
nucleotide exchange factor 1 (VAV1) is reported to be
overexpressed in clinical pancreatic carcinoma cells,
leading to activation of Rac1 signaling, resulting in de-
creased survival in pancreatic cancer patients [12, 13].
VAV guanine nucleotide exchange factor 2 (VAV2) is
hyperactivated in head and neck squamous cell carcin-
oma, and its molecular role was assessed by VAV2-
silencing; this investigation revealed that inactivated
Rac1 signaling leads to a decreased invasiveness of can-
cers [14]. Another example signifying the crucial roles of
GEFs in cancer development is the identification of the
chromosomal rearrangement in acute myelogenous
leukemia (AML) that results in the generation of the fu-
sion protein MLL-ARHGEF12 [15]. These reports sug-
gest the potentially significant roles of RhoGEFs in
tumorigenesis.
Rho guanine nucleotide exchange factor 15 (ARH-
GEF15) has been reported to function as a Rho-specific
GEF. Recently, an additional function of ARHGEF15 was
found: disruption of the ARHGEF15 gene led to delayed
extension of vascular networks and consequent reduc-
tion of the total vessel area in the retina [16]. However,
there have been only a few reports on the significance of
ARHGEF15, and the precise functions of ARHGEF15 in
PDAC remain elusive.
In this study, we attempted to identify genes whose ex-
pressions are correlated with a poor prognosis in pa-
tients with PDAC by global expression microarray
analysis of clinical samples, and investigated how the
identified genes were involved in the development of
cancer at the molecular level. At the outset, we found
that ARHGEF15 was overexpressed in the tumors in
PDAC patients with a poor prognosis. In addition, ARH-
GEF15 was shown to facilitate cell growth and cell mo-
tility in PDAC cell lines. Our data indicated that
ARHGEF15 promotes the development of the aggressive
features of PDAC, and could serve as a biomarker for
assessing the aggressiveness and predicting the prognosis
of PDAC patients, and also serve as a potential target for
the development of treatments directed against PDAC.
Results
Clinicopathologic characteristics of PDAC patients
Tumor samples from a total of 39 patients with pancre-
atic ductal adenocarcinoma (PDAC) were collected be-
tween 2002 and 2010, and subjected to molecular
profiling using DNA microarrays. Details of the clinical
characteristics of the patients are presented in Table 1.
Among the PDAC patients, there were 27 male and 12
female patients, respectively, with an overall median age
of 64.5 years (range, 42 to 78 years). The median overall
survival (OS) was 17.5 months (range, 1.7 to
62.8 months), and the pathological stage ranged from I
to IVb. No statistically significant relationship was found
between the OS and any of the patient characteristics,
including the gender, age, tumor histology, tumor size,
tumor location or the pathologic stage (Table 1, p > 0.05,
log rank test).
The ARHGEF15 expression level was elevated in the
tumor tissues of PDAC patients with a poor Prognosis
To identify the molecular mechanism underlying the ex-
ceptionally poor prognosis of PDAC, we performed a
global gene expression analysis using the Affymetrix
X3P GeneChip microarray, and carried out an analysis
of the prognosis in relation to the tumor gene expression
profiles of the 39 PDAC patients enrolled in the study.
The samples were divided into two groups: the poor
prognosis group, in which the OS was shorter than the
median OS, and the better prognosis group, in which
the OS was longer than the median OS. We found that
the expressions of 46 genes were significantly correlated
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with the OS in the PDAC patients (Additional file 1:
Table S1, p < 0.0001). Of the 46 genes, 32 were overex-
pressed in the worse prognosis group, whereas 14 were
overexpressed in the better prognosis group (Fig. 1a).
The top five most differentially expressed genes between
the poor prognosis group and better prognosis group
were HNF1B, ARHGEF15, SEPT6, MATR3 and PMSE4.
The gene showing the most significant differential ex-
pression was HNF1B (Additional file 2: Figure S1, p <
0.00001), known as a transcription factor, whose higher
expression level in the PDAC specimens was correlated
with a worse survival of the patients [17]. On the other
hand, the relationships between the other 4 genes and
the prognosis of the patients with PDAC have not been
reported to date.
To verify the differential expressions of the genes iden-
tified by microarray analysis, we performed independent
real-time RT-PCR analyses for ARHGEF15, SEPT6,
MATR3, and PMSE4. In the RNA samples obtained
from the 39 formalin-fixed tumors that were analyzed,
reliable data were obtained for 35 samples, as judged
from the expression of ACTB, the internal control gene.
Real-time RT-PCR analysis showed higher expression
levels of the ARHGEF15, SEPT6 and MATR3 genes
among the four genes in the worse prognosis group as
compared to the better prognosis group. The results
were analyzed by constructing Kaplan-Meier plots and
compared by the log-rank test (Fig. 1b). In particular, the
patient with higher expression levels of ARHGEF15
showed a significantly shorter OS as compared to the
group showing lower ARHGE15 expression levels (me-
dian OS 14.0 months in the high ARHGEF15 expression
group vs. 26.2 months in the low ARHGEF15 expression
group; p < 0.01, log rank test). These data indicated that
ARHGEF15 upregulation might enhance the aggressive-
ness of PDAC cells, resulting in a worse prognosis of the
patients.
Analysis of ARHGEF15 expression in a pancreatic cancer
cell line panel
Since ARHGEF15 is a specific GEF for the Rho-family
proteins that is involved in multiple cancer signaling
pathways, we further investigated the molecular role of
ARHGEF15 in the development of PDAC using pancre-
atic cancer cell lines. We initially assessed the ARH-
GEF15 expression levels in 11 pancreatic cancer cell
lines by real-time RT-PCR analysis. As shown in Fig. 2a
and b, varied expression levels were observed in the cell
lines, with a maximum difference in the ARHGEF15 ex-
pression level of approximately 86-fold among the pan-
creatic cancer cell line panel. While the AsPC-1 and
MIAPaCa-2 cells showed lower ARHGEF15 mRNA ex-
pression levels, the Hs766T cells showed the highest ex-
pression levels. ARHGEF15 protein expression levels in
the three cell lines were also examined by Western blot-
ting, which revealed expression patterns consistent with
the mRNA expression patterns (Fig. 2c).
Gene silencing of ARHGEF15 decreased the amounts of
the activated forms of the Rho-family proteins
Since higher ARHGEF15 expression levels were associ-
ated with a worse prognosis, we attempted to investigate
the biological effects of overexpression or knockdown of
ARHGEF15 on the cellular phenotype using pancreatic
cancer cell lines. First, we examined the effect of gene si-
lencing of ARHGEF15 by RNA interference in the
Hs766T cells, which showed the highest endogenous ex-
pression levels of ARHGEF15 among the pancreatic cell
line panel, as shown in Fig. 2a. We confirmed by real-
time RT-PCR that small-interfering (si) RNAs for ARH-
GEF15 (siARHGEF15s) suppressed the ARHGEF15
mRNA expression level by more than 80 % as compared
to the control cells (Fig. 3a). ARHGEF15 protein
Table 1 Patient characteristics
Characteristic P value












Primary tumor size(mm) 0.38
Median 28
Range 10–90











Abbreviations: Pb Pancreatic body, Ph Pancreatic head, Pt Pancreatic tail, Phb
Pancreatic head and body
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expression was also examined by Western blotting,
which revealed expression patterns consistent with the
mRNA expression patterns. Given the fact that the Rho-
family proteins are direct downstream effectors of ARH-
GEF15, the amounts of activated RhoA, Rac1 and Cdc42
were determined in the ARHGEF15-silenced cells; pull-
down assay was conducted to measure the amounts of
GTP-bound activated RhoA, Rac1 and Cdc42. Lysates of
HeLa cells treated with GTP as positive controls showed
increased amounts of the activated forms of the Rho-
family proteins, while the lysates of the cells treated with




Fig. 2 Varied ARHGEF15 expression levels in the pancreatic cancer cell lines. The ARHGEF15 mRNA expression levels were determined in 11
pancreatic cancer cell lines by real-time RT-PCR (n = 3). The relative gene expression levels of ARHGEF15 represented in fold values relative to the
minimum expression level in the AsPC-1 cells (a and b). c The protein expression levels of ARHGEF15 in Hs766T, MIAPaCa-2 and AsPC-1 cells
were determined by Western blotting (n = 3)
a
b
Fig. 1 High ARHGEF15 expression levels in pancreatic cancers are associated with a poor prognosis. a A heatmap of differentially expressed
genes was determined by Affymetrix X3P GeneChip microarray analysis in specimens obtained from 39 PDAC patients. The top five most
differentially expressed genes between the poor prognosis and better prognosis groups are listed. b Kaplan-Meier estimates of the relationships
between the expression levels of ARHGEF15, SEPT6 and MATR3 in the tumors by separate real-time RT-PCR analyses and the prognosis of the
PDAC patients
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the activated forms of the Rho-family proteins, confirm-
ing the specificity of the assay (Fig. 3b). ARHGEF15 gene
silencing in Hs766T cells reduced the amounts of acti-
vated GTP-RhoA, -Rac1 and -Cdc42 at 72 h (Fig. 3c and
Additional file 3: Figure S2a). Then, we investigated the
effect of ARHGEF15 overexpression on the amounts of
the activated forms of the Rho-family proteins. Both
AsPC-1 and MIAPaCa-2 cells, which showed low en-
dogenous expression levels of ARHGEF15, were transi-
ently transfected with an expression vector encoding
ARHGEF15. Detection of the Halo tag attached to the
ARHGEF15 protein confirmed that more than 50 % of
the cells overexpressed the exogenous ARHGEF15
(Fig. 3d and e). Pull-down assay for active Rho-family
proteins showed that the levels of GTP-bound active
RhoA, Rac1 and Cdc42 were significantly increased in
the AsPC-1 cells that showed ARHGEF15 overexpres-
sion (Fig. 3f ). ARHGEF15 overexpression in MIAPaCa-2
cells was also associated with a tendency towards in-
crease in the amounts of active Rho-family proteins.
Collectively, the results indicate that both gene silencing
and overexpression of ARHGEF15 modulate the degree
of activation of the Rho-family proteins.
ARHGEF15 promotes cancer cell motility
Rho-family GTPases are critical intracellular signaling
molecules that regulate cytoskeleton organization, gene
expression, cell cycle progression and cell motility [3].
Therefore, we examined whether activation of the Rho-
family proteins by ARHGEF15 affected the aggressive-
ness of the pancreatic cancer. The effect of the ARH-
GEF15 expression level on the cellular motility was
a b c
d e f
Fig. 3 ARHGEF15 expression is associated with activation of the Rho-family proteins in several cell lines. a ARHGEF15 expression levels in untreated Hs766T
cells (Ctrl), Hs766T cells treated with negative control siRNA (siNC) or siRNA for ARHGEF15 were assayed by both real-time RT-PCR and Western blotting.
b Confirmation by the active RhoA/Cdc42/Rac1 pull-down assay. HeLa cell lysates treated with GDP (to inactivate the Rho-pathway proteins) or GTP
(to activate the Rho-pathway proteins) were subjected to pull-down assay for the active Rho-family proteins to examine the degree of activation of the
Rho-family proteins. c RhoA, Cdc42 and Rac1 activation in Hs766T cells after knockdown of endogenous ARHGEF15 measured by the active RhoA/Cdc42/
Rac1 pull-down assay. Overexpression of ARHGEF15 in d AsPC-1 cells and e MIAPaCa-2 cells. RhoA, Cdc42 and Rac1 activation in f AsPC-1 cells and g
MIAPaCa-2 cells transfected with the ARHGEF15 expression vector assessed by the active RhoA/Cdc42/Rac1 pull-down assay (n= 3). The scale bars
represent 200 μm
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investigated using the transwell and wound healing as-
says. As shown in Fig. 4a, gene silencing of ARHGEF15
caused a notable reduction in the number of Hs766T
cells, as compared to the control cells, migrating
through the holes in the filters of the transwell cham-
bers. In addition, we assessed the effect of ARHGEF15
gene silencing on the migration of cells into the scratch
wound area at 24 h after generation of the wound in the
presence of the cells. While almost complete closure of the
entire wound area was observed in the control cells, the
wound closure area decreased in the cells treated with
siARHGEF15 (Fig. 4b). The retarding effect on wound heal-
ing and migration was confirmed again by using two differ-
ent siRNA sequences for ARHGEF15. In addition, we
assessed the effect of ARHGEF15 overexpression on the
motility of the AsPC-1 and MIAPaCa-2 cells by the trans-
well and wound healing assays. ARHGEF15 overexpression
in both of these cell lines was associated with a significant
increase in the number of migrating cells in both the trans-
well (Fig. 5a and b) and wound healing (Fig. 5c) assays, con-
sistent with the phenotypes of ARHGEF15 gene silencing.
ARHGEF15 is involved in pancreatic cancer cell
proliferation
In addition to promoting cell motility, the Rho-family
proteins are also critical intracellular signaling molecules
that contribute to cell growth through associating with
various proteins. We next examined whether modulation
of ARHGEF15 expression affected the proliferation of
pancreatic cancer cell lines, using Cell Counting Kit-8, a
colorimetric modified MTT assay kit. First, we examined
the effect of suppression of ARHGEF15 on the growth
rate of Hs766T cells which were demonstrated to show
high endogenous ARHGEF15 expression levels. As
shown in Fig. 6a, the Hs766T cells treated with siARH-
GEF15s showed a 44.7 % and 36.7 % decrease of the cell
proliferative activity at 72 h as compared to the controls.
The decreased cell proliferation was confirmed by an in-
dependent time-course assay using a different siRNA for
ARHGEF15 (Additional file 3: Figure S2a). Next, we
assessed the effect of ARHGEF15 overexpression on the
growth rate of the AsPC-1 and MIAPaCa-2 cells, which
revealed an approximately 60 % increase in the
a
b
Fig. 4 ARHGEF15 depletion decreases the cellular motility. a Cell migration and invasiveness of Hs766T cells (n = 4) following knockdown of
ARHGEF15 were examined by the transwell chamber assay. The scale bars represent 500 μm. Graphs below the pictures indicate the numbers of
the migrated cells. Statistical analysis was conducted by Student’s t-test as shown (**p <0.01). b Scratch wound healing assay in Hs766T cells after
ARHGEF15 gene silencing (n = 4). Dotted lines represent the cell fronts at the gaps. The scale bars represent 500 μm
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proliferative activity of the AsPC-1 cells, and approxi-
mately 30 % increase in the proliferative activity of the
MIAPaCa-2 cells at 72 h (Fig. 6b). The time-course
study of ARHGEF15 overexpression also confirmed the
effect of ARHGEF15 overexpression of enhancing the
proliferative activity of the pancreatic cells (Additional
file 3: Figure S2b). The results of the upregulation and
downregulation experiments led us to infer that ARH-
GEF15 overexpression in the tumor contributes to the
aggressiveness of PDAC.
Finally, we assessed the effect of a RhoA inhibitor
(CCG-1423) and RhoA gene silencing on the cellular
phenotypes to obtain evidence in support of our find-
ings. In accordance with the observation found in associ-
ation with ARHGEF15 depletion, both the RhoA
inhibitor and RhoA gene silencing reduced the prolifera-
tive activity, migration and invasiveness of the cancer
cells (Fig. 7a–d).
Discussion
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most aggressive cancers, and is associated with an ex-
tremely poor prognosis [1, 2]. We attempted to identify
genes whose overexpression in the tumor might be cor-
related with a poor prognosis in PDAC patients by a glo-
bal expression microarray analysis of clinical samples
obtained from Japanese patients.
Although overexpression of several genes, including
HNF1B, CA19-9 and miR-192, have been reported previ-
ously as poor prognostic factors in PDAC patients [17–
19], we found for the first time that ARHGEF15 overex-
pression was also associated with an extremely poor
prognosis of PDAC patients. Patients showing high ex-
pression levels of ARHGEF15 showed a statistically sig-
nificantly shorter survival as compared to those showing
low expression levels of ARHGEF15. Taking into consid-
eration the numerous reports suggesting that the Rho-
GEFs contribute to various steps of oncogenesis and to
worsening of the prognosis of cancer patients [12, 13,
15, 20], it would be reasonable to conclude that ARF-
GEF15 worsens the prognosis of PDAC patients through
facilitating migration and proliferation of the pancreatic
cancer cells.
We showed that increased ARHGEF15 expression ac-
tivated the Rho-family proteins, leading to enhanced cell
motility in pancreatic cell lines. Molecular analysis to
elucidate the mechanism by which activated Rho-family
proteins increase the cellular motility was not conducted
in the present study. However, the sequence of events
from activation of the Rho-family proteins to increase of
the cellular motility could be explained by the following
well-established molecular mechanism reported previ-
ously; RhoA directly promotes phosphorylation of the
regulatory myosin light chain, promotes organization of
the actin stress fibers, and promotes the formation of focal
adhesions [21]. This is consistent with the previous report
that RhoA is activated at the leading edge of migrating
cells [22]. Furthermore, Rho-family proteins bind several
effector proteins, mediating downstream signaling. ROCK
as one of the effector proteins facilitates contractility of
a b c
Fig. 5 ARHGEF15 overexpression enhances the cellular motility. a and b Cell migration and invasiveness assay of AsPC-1 and MIAPaCa-2 cells
(n = 4) following overexpression of ARHGEF15 was conducted using a transwell chamber. The scale bars represent 500 μm. The graphs below the
pictures show the numbers of the migrated cells. Statistical analysis was conducted by Student’s t-test as shown (**p <0.01). c Scratch wound
healing assay in MIAPaCa-2 cells showing ARHGEF15 overexpression (n = 4). Dotted lines represent the cell fronts at the gaps. The scale bars
represent 500 μm
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muscle fibers and stress fiber formation [23]. Other
examples of Rho effector proteins are mammalian
homolog of Drosophila diaphanous (mDia) and phos-
phatidylinositide 4P 5kinase (PI4P-5 K) which en-
hance and promote reorganization of F-actin assembly
in the filopodia [24, 25]. We showed that upregula-
tion of ARHGEF15 in pancreatic cancer increased ac-
tivation of the Rho-family proteins, especially RhoA,
Cdc42 and Rac, resulting in enhanced motility of the
pancreatic cancer cells. We speculate that the ob-
served phenotypes related to motility in the study of
ARHGEF15 dysregulation were mediated by the
above-mentioned sequential molecular events result-
ing in the promotion of stress fiber formation.
In addition to the reduced cellular motility mediated
by suppression of Rho signaling observed upon gene si-
lencing of ARHGEF15, we found, unexpectedly, that
ARHGEF15 also promoted the proliferation of the pan-
creatic cancer cells. However, several previous studies
have demonstrated that overexpression of the Rho-
family proteins together with enhanced Rho signaling
was involved in the proliferation of cancer cells in many
malignant tumors [14, 26–28]. Ghosh PM et al. reported
that the PI3K pathway is involved in the enhancement of
cellular proliferation induced by RhoA [29]. Zhang S et
al. reported that RhoA activation is crucial for cell cycle
progression of gastric cancer cells, and both activation
of the RhoA-ROCK pathway and regulation of the CDKs
a
b
Fig. 6 ARHGEF15 overexpression promotes cell growth. a Cell growth after knockdown of ARHGEF15 in Hs766T cells was examined at 72 h by a
colorimetric modified MTT assay (n = 4). b Cell proliferation in response to ARHGEF15 overexpression was assessed at 72 h in AsPC-1 and
MIAPaCa-2 cells by a colorimetric modified MTT assay (n = 4). Statistical analysis was conducted by Student’s t-test as shown (**p <0.01)
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are involved in the cell cycle regulation by RhoA [27].
On the other hand, recent observations have revealed
that small-molecule inhibitors targeting RhoA, such as
Rhosin and Y16, not only suppress the cellular motility,
but also suppress the proliferative activity of cancer cells
in vitro [30, 31]. Y-27632, another RhoA pathway inhibi-
tor, was shown to cause cellular apoptosis in some can-
cer cell lines [32]. In addition to RhoA inhibitors,
Cdc42-selective inhibitors have also been reported to de-
crease the cellular motility [33]. AZA1, an inhibitor of
both Rac1 and Cdc42, was also found to suppress cellu-
lar proliferation both in vitro and in vivo [34]. Moreover,
Kusuhara S et al. found that ARHGEF15 promotes ret-
inal neovascularization [16]. These reports lend support
to our findings that in addition to enhancing the motility
and invasiveness of the cancer cells, ARHGEF15 also
regulates the proliferation of pancreatic cancer cells.
We showed that depletion of ARHGEF15 in pancreatic
cancer cells by small-interfering RNA caused inactiva-
tion of the Rho-family proteins, as shown in Fig. 3,
resulting in suppression of both the motility and prolif-
erative activity of the pancreatic cancer cells. Further-
more, we demonstrated that RhoA inactivation by gene
silencing and RhoA inhibition (CCG-1423) suppressed
both the cellular proliferative activity and motility of the
cancer cells (Fig. 7a–d). These findings suggest that
ARHGEF15 could serve as a therapeutic target for the
development of treatments against pancreatic cancer,
and that ARHGEF15 inhibition might have anti-cancer
effects, including metastasis-inhibitory effect, anti-
proliferative effect and anti-angiogenic effect, via sup-
pressing activation of the Rho-family proteins. Accumu-
lating evidence suggests that GEFs could be target
proteins which can be inhibited by small molecules. Ex-
amples include a natural product named Brefeldin A,
which targets the catalytic domain of GEF [35], and
LM11 screened in silico, which binds to the GEF-GDP
complex suppressing downstream signaling transduction
[36]. These findings of chemical trackability together
with our biological finding of the role of ARHGEF15
might pave the way for the development of treatments
for patients with PDAC in the future. The effects of se-
lective ARHGEF15 inhibition and also of ARHGEF15 in-
hibition on other tumor types remain to be determined
in future studies.
Conclusions
In summary, we found that overexpression of ARH-
GEF15 in PDAC patients was associated with enhanced
growth and motility of pancreatic cancer cells, resulting
in a significantly worse prognosis of the patients. Our
findings in this study suggest that ARHGEF15 could




Fig. 7 RhoA inhibition decreases both the proliferative activity and motility of the cancer cells. a RhoA expression levels in Hs766T cells treated
with negative control siRNA (siNC) or siRNAs for RhoA were assayed by Western blotting. b and c Cell growth in Hs766T cells after knockdown of
RhoA and treatment with the RhoA-specific inihibitor, CCG-1423, was examined at 72 h by a colorimetric modified MTT assay (n = 4). Statistical
analysis was conducted by Student’s t-test as shown (**p <0.01). d Cell migration and invasiveness assays of Hs766T cells with gene silencing of
RhoA and treated with 2.8 μM of CCG-1423 (n = 4) were conducted using a transwell chamber. The scale bars represent 500 μm
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especially benefiting the subpopulation of patients show-
ing overexpression of ARHGEF15 in the tumor cells.
Methods
Tumor specimens
Formalin-fixed, paraffin-embedded (FFPE) specimens of
pancreatic ductal adenocarcinoma were collected from
patients (n = 39) at the Department of Pathology, Kur-
ume University School of Medicine (Kurume, Japan),
from 2002 to 2010. Ethical approval for the study was
given by both the Kurume University Ethics Committee
and the Research Ethics Review Committee of Taiho
Pharmaceutical Co., Ltd. The permitted study numbers
are 10203 at Kurume University and S10-010 at Taiho
Pharmaceutical Co., Ltd. Informed consent was obtained
from each patient prior to participation in the study.
The present clinical study was carried out in compliance
with the principles laid down in the Helsinki Declar-
ation, as well as the guidelines of the institutional Ethics
Committees. The patients’ prognoses were determined
based on the clinical follow-up data obtained from the
patients’ medical records, and the overall survival was
measured from the day of surgery.
Microarray analysis
All FFPE blocks were sectioned into 4-μm-thick sections
with a Leica SM2010R microtome (Leica Microsystems
K.K., Tokyo, Japan) using an RNase-free technique, and
mounted on Superfrost slides. Two slides were prepared
for each block: one stained with hematoxylin and eosin,
and the other used for the subsequent RNA extraction.
The tumor areas of the tissue sections were macro-
dissected and RNA from these areas was isolated,
linearly amplified and hybridized to the Affymetrix Gen-
eChip Human X3P Array (Affymetrix, Santa Clara, CA,
USA) using labeling methods, in accordance with the
manufacturer’s instructions for the Arcturus Paradise
PLUS Reagent System (Life Technologies, Grand Island,
NY, USA) and GeneChip 3’ IVT Express Reagent kit
(Affimetrix). Affymetrix array CEL files were processed
by the RMA algorithm [37] to obtain probe set-level
gene expression data, using the Expression Console soft-
ware (Affymetrix). Hierarchical clustering of the micro-
array data was performed using the MATLAB software
(The MathWorks, Natick, MA, USA). The R survival
package was used for the survival analysis.
Cell culture, plasmid, siRNA and RhoA inhibitor
The human pancreatic cancer cell lines AsPC-1, MIAPaCa-
2, CFPAC-1, CAPAN-1, CAPAN-2, SU.86.86., BxPC-3,
CoLo587, Panc-1 and Hs766T were purchased from
American Type Culture Collection (ATCC, Rockville, MD,
USA), while the KP-4 cell line was purchased from the Jap-
anese Collection of Research Bioresources Cell Bank (JCRB
Cell Bank, Osaka, Japan). Cells were cultured in the recom-
mended media supplemented with fetal bovine serum and
the required reagents. All cells were incubated at 37 °C in a
humidified atmosphere containing 5 % CO2. The Halo-
tagged ARHGEF15 expression vector pFN21A was pur-
chased from Promega (Madison, WI, USA). The
small-interfering RNAs (siRNA) against ARHGEF15
(ARHGEF15HSS117853 and ARHGEF15HSS117854)
and RhoA (RHOAVHS40471 and RHOAHSS100655)
were purchased from Life Technologies. CCG-1423, a
RhoA-specific inhibitor, was purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Cell viability assay
The cell viability was quantified by a colorimetric modi-
fied MTT assay using Cell Counting Kit-8 (Dojindo, Ku-
mamoto, Japan), in accordance with the manufacturer’s
instructions. Cells were seeded on to four wells of 96-
well plates at a density of 5 × 102 cells/well. The cell via-
bility assay was performed 72 h after the seeding. Ten
μL of Cell Counting Kit-8 was then added to each well.
After incubation at 37 °C for 4 h, the absorption at
570 nm was measured using a microplate reader. The
proliferative activities of the cells transfected with siRNA
or plasmid were also quantified at 72 h after the trans-
fection by a colorimetric assay.
Transwell migration and invasiveness assay
Cell migration assays were performed using transwell
chambers (24-well, 8-μm pore size; Corning, Corning,
NY, USA) and cell invasiveness assays were conducted
using BD Falcon Cell culture inserts coated with BD
matrigel matrix (24-well, 8-μm pore size; BD Bioscience,
San Jose, CA, USA). About 1 × 105 cells in DMEM con-
taining 0.5 % serum were loaded into the upper cham-
bers. The lower chambers were filled with the same
medium supplemented with 10 % FBS. The plates were
incubated at 37 °C for 12 h. Cells that did not migrate
through the pores were removed with a cotton swab.
Cells on the lower side of the insert filter were fixed with
10 % formalin and stained with hematoxylin and eosin.
The number of cells on the underside of the filter was
counted.
Wound-healing assay
Scratch wound-healing assays were performed in 24-well
tissue culture plates (Corning). At 24 h after the cells
were seeded (by which time, the cell confluence usually
reached 90–100 %), scratches were made using the tip of
a 200-μL pipette. The wells were then washed twice with
the medium and cultured for an additional 24 or 48 h,
followed by assessment of the wound area.
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Active RhoA, Cdc42 and Rac1 pull-down assay
Cells were grown in 10-cm dishes, starved in serum-free
medium for 24 h and then stimulated with 10 % fetal bo-
vine serum for 2 h. Then, the cells were lysed in a buffer
containing 20 mM Tris–HCl, pH 7.6, 100 mM NaCl,
1 % Triton-X-100, 10 mM MgCl2, 2 mM NaF, and prote-
ase inhibitors. The lysates were clarified and the protein
concentrations were determined by the bicinchoninic
acid protein assay (Thermo Fisher Scientific, Waltham,
MA, USA) and normalized. Cell lysates of HeLa cell
lines were treated with GTP or GDP and used as posi-
tive or negative controls to assess the validity of the
pull-down assay [38, 39]. The amounts of GTP-bound
RhoA, Cdc42 and Rac1 in equal amounts of total protein
were enriched and extracted using their affinity for the
downstream effector proteins. The pull-downs (active
RhoA, Cdc42 or Rac1) and cell extracts (total RhoA,
Cdc42 or Rac1) were analyzed by SDS-PAGE followed
by Western blotting with a RhoA-, Cdc42- or Rac1-
specific antibody, respectively. Proteins were separated
by 4–15 % SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and electroblotted on to polyvinylidene
difluoride membranes. After blocking, the membranes
were probed with primary antibodies against RhoA,
Cdc42 and Rac1. Subsequently, after incubation with
horseradish peroxidase-conjugated secondary antibodies,
the antigen-antibody complexes were visualized using
enhanced chemiluminescence (Thermo Fisher Scien-
tific). Images were captured using an image analyzer
(LAS 3000; Fuji Film, Tokyo, Japan).
Western blotting
Pancreatic cancer cells were lysed using a radioimmuno-
precipitation assay buffer (Thermo Fisher Scientific)
containing protease inhibitors and phosphatase inhibi-
tors. The lysates were clarified and the protein concen-
trations were determined by the bicinchoninic acid
protein assay (Thermo Fisher Scientific) and normalized.
Proteins were separated by 4–15 % SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and electroblotted on to
polyvinylidene difluoride membranes. After blocking in
3%FBS in wash buffer (0.2 M Tris-HCl, pH 7.6, 1.5 M
NaCl, 0.1 % Tween 20), the membranes were incubated
with the specific primary antibodies against ARHGEF15
(Santa Cruz Biotechnology, Dallas, TX, USA) diluted in
blocking solution, at the appropriate dilutions. To ensure
equal loading, the membranes were probed with anti-β-
Actin antibody (Sigma-Aldrich). The membranes were
then washed five times, incubated at room temperature
for 1 h with a secondary antibody diluted in 5 % non-fat
milk in wash buffer. After an additional five washes, the
proteins were detected using ECL Western Blotting De-
tection Reagent, in accordance with the manufacturer’s
protocol.
Stealth RNA-mediated interference and overexpression
assays
Cells were transfectedwith stealth RNA-mediated interference
(RNAi; Life Technologies) for ARHGEF15, RhoA or stealth
RNAi negative control (Life Technologies) using Lipofecta-
mine RNAiMAX (Life Technologies), in accordance with the
manufacturer’s protocol. TheHalo-taggedARHGEF15 expres-
sion vector pFN21Awas transfected using theViafect transfec-
tion kit (Promega), in accordance with the manufacturer’s
protocol. All the experiments, both those involving downregu-
lation of ARHGEF15/RhoA, and those with overexpression of
ARHGEF15were carried out using transient assays.
Quantitative real-time reverse-transcriptase PCR
quantification
Total RNA was isolated from the cells using the RNeasy
Mini kit (Qiagen, Venlo, Netherlands). For the clinical
PDAC analysis, total RNA was extracted from the tumor
area using the Arcturus Paradise PLUS Whole Transcript
Reverse Transcription Kit (Life Technologies), in accord-
ance with the manufacturer’s protocol. The cDNAs were
synthesized using the Vilo Reverse Transcription kit (Life
Technologies). Reactions were carried out using the Taq-
Man Gene Expression Master Mix (Life Technologies) in
an ABI Prism 7900 platform (Life Technologies), in accord-
ance with the manufacturer’s protocol. ACTB was used to
normalize the gene expressions (ΔCt) and 2−ΔΔCt to calcu-
late the mRNA expression levels. The following primers
and probe sets were used to analyze the respective genes:
Hs01060665_g1 for ACTB, Hs00209087_m1 for ARH-
GEF15, Hs00938813_m1 for SEPT6, Hs00251579_m1 for
MATR3 and Hs01056041_m1 for PMSE4 (Life Technolo-
gies). If the Ct value of ACTB in real-time RT-PCR was less
than 35, the data were used to calculate the gene expression
level. The relative quantification of ARHGEF15 was per-
formed using the comparative cycle threshold method.
Statistical analysis
Statistical analysis to determine the significances of dif-
ferences in the proliferative activity and motility of the
cells was conducted using a two-tailed Student’s t-test.
P-values of <0.05 were considered as denoting statistical
significance. Error bars represent standard deviations.
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